Backs FY25 adjusted EBITDA $41M-$44M. The company said, “We believe continued growth in our clinical volumes, including NGS testing, will drive performance in the fourth quarter while positioning us to enter 2026 with increased momentum. Our relentless focus on the customer experience, which is enabled by our broad, oncology-centric test menu, world class commercial organization, and balanced geographic footprint, continues to differentiate us in the community setting, where approximately 80% of cancer care is delivered. At NeoGenomics (NEO), our goal has long been to bring the latest cancer testing innovation to community hospitals and oncologists, where it’s needed most, and I believe we have become the ‘partner of choice’ for these clinicians who strive every day to achieve the best possible outcomes for their patients. I am as optimistic as ever for what the future holds for our company.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NEO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- NeoGenomics price target raised to $12 from $10 at TD Cowen
- NeoGenomics Buy Rating: Strategic Product Launches and Management Changes Drive Growth Potential
- NeoGenomics price target raised to $11 from $6.50 at Stephens
- Dell reports ‘beat and raise,’ Caterpillar sees big tariff impacts: Morning Buzz